High Amylose Wheat Starch for Bowel Health
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Wheat starch composition, particularly in bread, pasta, and noodles, lacks variation in resistant starch content, limiting its potential to improve bowel and metabolic health due to its low amylose levels and inefficient starch biosynthesis processes, making it less effective in reducing glycemic index and promoting bowel health compared to other cereals like maize and barley.
Innovation Solution
Modifying wheat plants to increase the proportion of amylose in their starch to at least 30% by reducing the activity of starch branching enzyme IIa (SBEIIa) and potentially SBEIIb, which enhances the production of resistant starch and lowers the glycemic index, thereby improving bowel and metabolic health when consumed.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If wheat starch is used in processed foods, then it provides a stable and reliable food source, but it has low amylose content which limits its ability to improve bowel health and lower glycemic index
Solution Approach 1:
The patent applies parameter changes by modifying the starch composition parameters of wheat through genetic modification. Specifically, it changes the amylose content parameter from typical wheat levels (15-25%) to high amylose levels (30-80%), thereby altering the starch's functional properties to improve bowel health and glycemic control while maintaining wheat's reliability as a food source
Solution Approach 2:
The invention creates a composite starch system by combining modified high-amylose wheat starch with other food components. The modified starch retains the stability and reliability of traditional wheat starch while adding the health benefits of high amylose content, effectively creating a composite material that integrates both stability and health-improving properties
2Adaptability or versatility
If wheat starch composition is modified to increase amylose content, then resistant starch production increases and glycemic index decreases, but the starch biosynthesis process becomes more complex
Solution Approach 1:
The patent modifies the starch biosynthesis process by changing key enzymatic parameters - specifically reducing the activity of starch branching enzymes (SBEIIa and SBEIIb). This parameter change shifts the starch synthesis pathway to produce higher amylose content, thereby increasing resistant starch production and lowering glycemic index without requiring complete redesign of the biosynthesis process
Solution Approach 2:
The invention extracts and selectively reduces the function of specific enzymes (SBEIIa and SBEIIb) that are responsible for starch branching. By taking out or reducing these specific enzymatic functions while maintaining other biosynthesis processes, the patent achieves high amylose content and improved health properties without making the entire biosynthesis process complex
3Reliability
If wheat plants are modified to increase amylose proportion, then bowel health indicators improve, but the modification process and enzyme activity reduction becomes technically challenging
Solution Approach 1:
The patent applies parameter changes by modifying the genetic expression parameters of starch branching enzymes. Through changes in gene expression levels and enzyme activity parameters, the invention achieves improved bowel health indicators while managing the technical challenges of plant modification through controlled genetic intervention rather than complex structural changes
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified wheat starch with increased amylose content provides improved bowel health indicators such as increased short-chain fatty acid production, fecal bulk, and reduced inflammation, while also stabilizing blood glucose levels and improving metabolic health by slowing glucose absorption.
Implementation Method 1
This fraction is resistant starch (RS) which, together with a variable fraction of NSP, is metabolised by the large bowel microflora (Topping & Clifton, 2001). Short chain fatty acids (SCFA) are major end products of this fermentation
Implementation Method 2
While starch can be digested (theoretically to completion) in the human small intestine, some escapes into the large bowel. This fraction is resistant starch (RS)
Data Source
AI summary
A method and composition for improving one or more indicators of bowel health or metabolic health in a mammalian animal. This comprises the delivering to the gastrointestinal tract of the animal an effective amount of an altered wheat starch in the form of or derived from the grain of a wheat plant. The proportion of amylose in the starch of the grain is at least 30% and/or the grain comprises a reduced level of SBEIIa enzyme activity and/or protein relative to wild-type grain.